Polyrizon Begins U.S. Clinical Study of Allergy Blocker

Raanana, Israel, Sept. 22, 2026 /CourierPR/ -- Polyrizon Ltd., a clinical-stage biotech company specializing in the development of innovative intranasal hydrogels, has announced the enrollment of the first patient in its U.S. clinical study to evaluate NASARIX (PL-14), the company’s investigational Allergy Blocker, in patients with seasonal allergic rhinitis (SAR). This milestone represents a significant step in the company’s transition into the clinical stage of development.

The prospective, multicenter, randomized, single-blind, two-arm study is designed to evaluate the efficacy, safety, and tolerability of NASARIX in adults with seasonal allergic rhinitis. Participants will be randomized 1:1 to receive either NASARIX Allergy Blocker or a saline nasal spray comparator. The study is expected to randomize 120 patients at 5 clinical sites in the United States.

The primary efficacy endpoint will assess the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between PL-14 and the saline comparator over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability.

This study marks a defining milestone for Polyrizon, as the company moves NASARIX into clinical evaluation in patients for the first time.

NASARIX is a non-pharmacological, drug-free, mucoadhesive hydrogel nasal spray designed to form a physical barrier within the nasal cavity. The barrier is intended to reduce contact between inhaled airborne allergens and the nasal mucosa, thereby helping alleviate symptoms associated with allergic rhinitis.

The study is designed to generate data regarding efficacy and safety under real-world seasonal allergen exposure.

Polyrizon is a clinical-stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays. These sprays form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain™, or C&C, hydrogel technology is comprised of a mixture of naturally occurring building blocks and is delivered in the form of nasal sprays. The company is further developing certain aspects of its C&C hydrogel technology, such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon is also developing certain aspects of its C&C hydrogel technology, such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.

The Litigation Reform Act of 1995 and other securities laws require the Company to disclose the following information: the NASARIX (PL-14) clinical study is expected to randomize 120 patients at 5 clinical sites in the United States. The primary efficacy endpoint will assess the difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between PL-14 and the saline comparator over the first 14 treatment days. Safety assessments will include the frequency and severity of treatment-emergent adverse events as well as assessments of local and overall tolerability. The fiscal year ended December 31, 2025 and subsequent filings with the Securities and Exchange Commission (SEC) are referenced, indicating the company’s commitment to transparency and compliance with regulatory requirements.